- 1、本文档共86页,可阅读全部内容。
- 2、原创力文档(book118)网站文档一经付费(服务费),不意味着购买了该文档的版权,仅供个人/单位学习、研究之用,不得用于商业用途,未经授权,严禁复制、发行、汇编、翻译或者网络传播等,侵权必究。
- 3、本站所有内容均由合作方或网友上传,本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺!文档内容仅供研究参考,付费前请自行鉴别。如您付费,意味着您自己接受本站规则且自行承担风险,本站不退款、不进行额外附加服务;查看《如何避免下载的几个坑》。如果您已付费下载过本站文档,您可以点击 这里二次下载。
- 4、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等,请点击“版权申诉”(推荐),也可以打举报电话:400-050-0827(电话支持时间:9:00-18:30)。
- 5、该文档为VIP文档,如果想要下载,成为VIP会员后,下载免费。
- 6、成为VIP后,下载本文档将扣除1次下载权益。下载后,不支持退款、换文档。如有疑问请联系我们。
- 7、成为VIP后,您将拥有八大权益,权益包括:VIP文档下载权益、阅读免打扰、文档格式转换、高级专利检索、专属身份标志、高级客服、多端互通、版权登记。
- 8、VIP文档为合作方或网友上传,每下载1次, 网站将根据用户上传文档的质量评分、类型等,对文档贡献者给予高额补贴、流量扶持。如果你也想贡献VIP文档。上传文档
查看更多
* 住院部分来看,各个协会的意见基本一致。 普通病房: b-内酰胺类+ 大环类、氟喹诺酮类 ICU: b-内酰胺类+ 大环类/氟喹诺酮类,或氟喹诺酮类单用,其中ATS更细致地划分有/无绿脓感染,但治疗方案还是与其他协会基本相似。 * Slide * Based on the national guidelines for initial empiric treatment of patients with hospital-acquired pneumonia (HAP), proposed by the American Thoracic Society (ATS), HAP is defined as pneumonia occurring 48 hours after admission and excluding any infection that is incubating at the time of admission. HAP is a major cause of morbidity and mortality, especially in the complex environment of the intensive care unit (ICU), and is the second most common nosocomial infection in the United States. The lack of sensitive diagnostic methods and the increasing prevalence of nosocomial pathogens with multiple antibiotic resistance complicate patient management. HAP patient deaths directly attributable to infection have been estimated to be as high as 50%, with even higher mortality rates if bacteremia or certain pathogens are involved1 * * Slide * The core organisms for group 1 include S. pneumoniae, methicillin-sensitive S. aureus (MSSA), H. influenzae, and enteric gram-negative bacilli. The ATS recommends monotherapy for HAP patients in this group, including second-generation cephalosporins, a ?-lactam/?-lactamase inhibitor combination (piperacillin/tazobactam, ticarcillin/clavulanate), or a non-pseudomonal third-generation cephalosporin (cefotaxime or ceftriaxone). A fluoroquinolone, or clindamycin plus aztreonam, may be considered for penicillin-allergic patients, provided that S. pneumoniae is ruled out. * Slide * The most challenging issue in treating HAP is selecting appropriate empiric antibiotics for patients in group 3. ATS recommends the addition of antimicrobial agents effective against P. aeruginosa and Acinetobacter species to the group 1 antibiotics; this includes an aminoglycoside or fluoroquinolone in combination with an antipseudomonal b-lactam, with or without a b-lactamase inhibitor (e.g., piperacillin/tazobactam), antipseudomona
您可能关注的文档
- 甲状腺合并心脏病临床治疗.ppt
- 检验知识培训.ppt
- 减肥与饮食习惯.ppt
- 简单介绍脊髓型颈椎病的近几年来出现的新的治疗方法.ppt
- 简明现代医学-肺癌.ppt
- 简要-急救知识.ppt
- 简易呼吸机的使用.ppt
- 建宁闽江源自助游.ppt
- 建筑方案设计做图科目考点分析2011版.ppt
- 建筑环境第1章-绪论.ppt
- DB44_T 2611-2025 城市排水管网有毒有害气体监测与风险分级管理技术标准.pdf
- DB44_T 2612-2025 竞赛类科普活动策划与实施服务规范.pdf
- DB43_T 2947-2024 烟草种子质量控制规程.pdf
- DB37_T 4836-2025 煤矿风量实时监测技术要求.pdf
- 叉车防撞系统,全球前22强生产商排名及市场份额(by QYResearch).docx
- 超滤膜,全球前18强生产商排名及市场份额(by QYResearch).docx
- DB62T 4172-2020 玉米品种 酒623规范.pdf
- DB62T 4160-2020 在用真空绝热深冷压力容器综合性能在线检测方法.pdf
- DB62T 4164-2020 辣椒品种 酒椒1号.pdf
- DB62T 4133-2020 公路隧道地质超前预报机械能无损探测技术规程.pdf
文档评论(0)